Davies Collison Cave

J&J-owned Janssen Pharmaceutica has sued Juno Pharmaceuticals, alleging the Australian off-patent drug maker is threatening to infringe its patent for a schizophrenia drug by seeking to list its own products on the PBS.

Nike has lost its challenge to a Canberra AFL club's trade mark, with IP Australia finding that the “arc-like feature” depicting a football in flight was not deceptively similar to the sportswear giant’s iconic swoosh mark.

IP boutique Davies Collison Cave has brought proceedings against its Melbourne landlord at the Orica House, seeking a declaration that it has not abandoned its lease.  

Puma has appealed its failed opposition to a trade mark for Tiger Woods' golf apparel and equipment brand Sun Day Red, which the German sneaker giant argued was too similar to its iconic leaping cat mark.

Samsung Bioepis has successfully opposed Janssen's bid to patent a monoclonal antibody to treat ulcerative colitis, but an IP Australia delegate has given the J&J-owned company a chance to fix its application.

Green iron startup Element Zero is challenging a bid by Fortescue for access to nine million seized documents in their trade secrets spat, saying its rival has not met the test for proving inadequate discovery of material.

The owner of luxury brand Van Cleef & Arpels has taken retailers Target and Kmart to court, alleging they infringed its trade marks and violated consumer law by selling jewellery that copy its hallmark clover and flower motifs worn by countless celebrities and royalty.

Biotech Regeneron and drug company Bayer have wasted no time in challenging a decision that cleared the way for generic pharmaceutical manufacturer Sandoz to launch a version of top selling Eylea.

A judge has expressed frustration over the fourth discovery fight this year in Fortescue’s trade secrets case against Element Zero, as the green iron startup claims its bigger rival is trying to drag out the litigation.

Regeneron and Bayer have lost their bid to block generic drug maker Sandoz from launching a biosimilar of their blockbuster eye drug Eylea.